The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
General Updates | Multiple myeloma in pregnancy: a rare but serious situation
Daan Dierickx, MD, PhD, KU Leuven and University Hospitals Leuven, Leuven, Belgium, briefly discusses the challenge of treating multiple myeloma (MM) during pregnancy, noting that although rare, this is a serious situation given the disease’s potentially aggressive nature. Prof. Dierickx notes that due to limited data on the safety of newer treatments, such as immunomodulators and proteasome inhibitors, older treatment modalities must be used, with termination of pregnancy also being a consideration. This interview took place virtually.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think this is the most difficult one because myeloma can be aggressive and fortunately it’s very rare during pregnancy, but it can be very aggressive and then when we have to treat it during the pregnancy we have to go back to our older treatments with steroids, with some chemotherapy and anthracycline or cyclophosphamide. Because the new treatments which are given for myeloma, the immune modulators, the proteasome inhibitors and so on, they are at this time, because we don’t have enough data, not indicated during the pregnancy so here I think this is the most problematic but fortunately it’s very very rare during pregnancy...
I think this is the most difficult one because myeloma can be aggressive and fortunately it’s very rare during pregnancy, but it can be very aggressive and then when we have to treat it during the pregnancy we have to go back to our older treatments with steroids, with some chemotherapy and anthracycline or cyclophosphamide. Because the new treatments which are given for myeloma, the immune modulators, the proteasome inhibitors and so on, they are at this time, because we don’t have enough data, not indicated during the pregnancy so here I think this is the most problematic but fortunately it’s very very rare during pregnancy. There we still need to go to older treatments, so there, termination of pregnancy should be discussed with the patient as well.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
